Sanctura trospium chloride fda approval date 2004?

When did the FDA approve Sanctura (trospium chloride)?
The FDA approved trospium chloride under the brand name Sanctura on August 5, 2004, allowing it to be marketed for overactive bladder in the United States. [1]

What does the approval date mean for patients and physicians?
Approval on that date gave clinicians a new antimuscarinic option for bladder control. It also set the schedule for post‑marketing safety studies required by the FDA to monitor long‑term effects.

How does Sanctura’s launch fit into the broader timeline of bladder‑relief drugs?
Sanctura was the third orally administered antimuscarinic approved for overactive bladder, following oxybutynin (approved 1992) and darifenacin (approved 2004). Its 2004 entry helped broaden treatment choices, particularly for patients who had intolerable side effects from earlier agents.

Who is behind Sanctura and when did it hit the market?
Sanctura is manufactured by Sanofi‑Synthelabo, a subsidiary of Sanofi. The drug was commercially released later in 2004, shortly after the FDA approval letter was issued.

What’s the current status of trospium chloride’s patent life?
The original patents that covered trospium chloride’s formulation expired several years after 2004, allowing generics to enter the market in 2018. The generic availability has expanded access while maintaining the drug’s clinical profile.

---

Sources
[1] https://www.drugs.com/monograph/trospium-chloride.html (approval date: August 5, 2004)